Professor Peter Sever Professor of clinic pharmacology and therapeutics, honorary consultant physician
- Patient age group
- Adults
- Consultant registered on
- 06/10/1969
- Primary medical qualifications
- MB.BChir.(Cantab). FRCP
- Gender
- Male
- Services
- Hospitals
Contact
- Phone
- 020 3313 7382
Adelle Ferguson Adom, secretary
Background
Professor Peter Sever trained at Trinity Hall, Cambridge and St Mary's Hospital Medical School.
Expertise
Hypertension
Research & publications
Hypertension, pathophysiology & treatment, clinical trials of blood pressure & lipid lowering treatment
Recent publications:
Sever PS, Dahlf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003:361;1149-1158.
Dahlf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Poulter NR, Sever PS on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of ?-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-480.
Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dhalof B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet, Sep 2015 Sep 18. pii: S0140-6736(15)00257-3. doi: 10.1016/S0140-6736(15)00257-3. [Epub ahead of print] PMID: 26414968
Brown MJ1, Williams B2, Morant SV3, Webb DJ4, Caulfield MJ5, Cruickshank JK6, Ford I7, McInnes G8, Sever P9, Salsbury J10, Mackenzie IS3, Padmanabhan S8, MacDonald TM3; British Hypertension Society's Prevention; Treatment of Hypertension with Algorithm-based Therapy (PATHWAY) Studies Group. Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes Endocrinol. 2015 Oct 16. pii: S2213-8587(15)00377-0. doi: 10.1016/S2213-8587(15)00377-0. [Epub ahead of print]
Mega JL1, Stitziel NO2, Smith JG3, Chasman DI4, Caulfield MJ5, Devlin JJ6, Nordio F7, Hyde CL8, Cannon CP7, Sacks FM9, Poulter NR10, Sever PS10, Ridker PM4, Braunwald E7, Melander O11, Kathiresan S12, Sabatine MS7. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015 Jun 6;385(9984):2264-71. doi: 10.1016/S0140-6736(14)61730-X. Epub 2015 Mar 4.